lovastatin has been researched along with Coronary Heart Disease in 268 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (4.10) | 18.7374 |
| 1990's | 184 (68.66) | 18.2507 |
| 2000's | 70 (26.12) | 29.6817 |
| 2010's | 3 (1.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albers, M; Baumeister, SE; Kroemer, HK; Meyer zu Schwabedissen, HE; Nauck, M; Rimmbach, C; Siegmund, W; Völzke, H; Wallaschofski, H | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Braunwald, E; Coady, S; Domanski, M; Fleg, J; Gosen, C; Kirby, R; Knatterud, G; Sachdev, V; Tian, X | 1 |
| Guo, WZ; Ji, H; Li, D; Lu, CL; Yan, ZH | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Irons, BK; MacLaughlin, EJ; McCall, K; Snella, KA; Villarreal, M | 1 |
| Mehta, JL; Singh, BK | 1 |
| Lucas, BD | 1 |
| Holme, I; Tonstad, S | 1 |
| Ferrières, J | 1 |
| Curran, MP; Goa, KL | 1 |
| Clark, LT | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Boden, WE | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Tellier, P | 1 |
| Klose, G | 1 |
| Hodis, HN; Mack, WJ; Mahrer, PR; Selzer, RH; Vigen, C | 1 |
| Cannon, CP; Ray, KK | 1 |
| Girotra, S; Mittleman, MA; Mukamal, KJ | 1 |
| Allen, SE; Brass, EP; Melin, JM | 1 |
| Plans-Rubió, P | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Gotto, AM | 3 |
| Frisinghelli, A; Mafrici, A | 1 |
| Fuster, V | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Ackerson, L; Avins, AL; Hwang, PM; Levin, TR; Levine, JG; Manos, MM; Murphy, R; Replogle, A; Watson, DJ; Zhao, W | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Kolata, G | 1 |
| Paoletti, R; Sirtori, CR; Tremoli, E | 1 |
| Oliver, MF | 2 |
| Chisholm, A; Crooke, M; Jackson, R; Mann, J; Neutze, J; North, D; Swinburn, B; White, H; Wilcox, J | 1 |
| Freed, M; Grines, CL; Jones, D; O'Neill, WW; Safian, M; Safian, RD | 1 |
| Thompson, GR | 2 |
| Larsen, ML | 1 |
| Hippisley-Cox, J | 1 |
| Gotto, AM; Jones, PH | 1 |
| Kjekshus, J; Pedersen, TR | 1 |
| Forti, N | 1 |
| Ravnskov, U | 3 |
| Jacobson, TA | 2 |
| Colquhoun, DM | 1 |
| Burns, K; Ellis, A; Haberl, E; Hook, N; Kellick, KA; McAndrew, E | 1 |
| Rasmusson, BU | 1 |
| Drown, DJ | 1 |
| Ostergaard Kristensen, B | 1 |
| Buja, LM; Casscells, SW; Goff, DC; Gould, KL | 1 |
| Durrington, PN | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Shepherd, J | 2 |
| Beigel, Y; Fainaru, M; Gavish, D; Neuman, Y; Teplitzky, Y; Wurzel, M; Zafrir, N | 1 |
| Richter, WO; Schwandt, P | 1 |
| Albers, JJ; Brown, BG; Hillger, L; Poulin, D; Zhao, XQ | 1 |
| Oyri, A | 1 |
| Pedersen, TR | 2 |
| Shaughnessy, AF; Slawson, DC | 1 |
| Gram, JB | 1 |
| Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V | 1 |
| Gram, J; Jespersen, J | 1 |
| Arndtz, N; Meiser, B; Reichart, B; Seidel, D; Thiery, J; von Scheidt, W; Wenke, K | 1 |
| Byington, RP; Furberg, CD | 1 |
| Faergeman, O; Haghfelt, T | 1 |
| Olsson, AG | 2 |
| Wennmalm, A | 1 |
| Wood, DA | 1 |
| Beamish, RE; Dhalla, NS | 1 |
| Betteridge, L; Chan, P; Clunn, G; Gallagher, K; Hughes, A; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
| Coupal, L; Grover, SA; Hamilton, VH; Racicot, FE; Zowall, H | 1 |
| Meiser, B; Reichart, B | 1 |
| Boccuzzi, SJ; Cedarholm, JC; DeMaio, SJ; Ivanhoe, R; King, SB; Klein, JL; Kosinski, AS; Stillabower, ME; Talley, JD; Weintraub, WS | 1 |
| Service, RF | 1 |
| Armitage, J; Collins, R; Fatemian, M; Kearney, E; Keech, A; Lawson, A; Lyon, V; MacMahon, S; Mindell, J; Wallendszus, K | 1 |
| Hunninghake, DB; Probstfield, JL | 1 |
| Engelhardt, JF; Grossman, M; Kozarsky, K; Lupien, PJ; Muller, D; Raper, SE; Stein, EA; Wilson, JM | 1 |
| D'Agostino, LC; D'Agostino, RB; Kannel, WB; Stepanians, MN | 1 |
| Albers, JJ; Brown, BG; Dowdy, A; Fisher, LD; Hillger, LA; Sniderman, AD; Stewart, BF; Zhao, XQ | 1 |
| Hathaway, SC; Paat, JJ; Paterson, RW; Steele, GH; Wong, JG | 1 |
| Goldstein, MR | 1 |
| Bonnier, H; Foley, DP; Jackson, G; Macaya, C; Serruys, PW; Shepherd, J; Vrolix, M | 1 |
| Carbonieri, E; Cemin, C; Franceschini, L; Ghebremariam-Tesfau, K; Rossi, L; Tomei, R; Zardini, P | 1 |
| Alaupovic, P; Azen, SP; Blankenhorn, DH; Cashin-Hemphill, L; DeBoer, LW; Hirsch, LJ; Hodis, HN; Kramsch, DM; Mack, WJ; Mahrer, PR; Masteller, MJ; Vailas, LI | 1 |
| Albers, JJ; Bisson, B; Brown, BG; Fisher, L; Hillger, L; Sacco, D; Zhao, XQ | 1 |
| Faxon, DP; Franklin, SM | 1 |
| Peres, RB; Plavinik, F; Ribeiro, AB; Zampieri, M; Zanella, MT | 1 |
| Carrier, M; Cartier, R; Genest, J; Leclerc, Y; Pelletier, GB; Pelletier, LC | 1 |
| Bondarenko, BB; Gurevich, VS; Kasennova, NI; Le Van Thach, TD; Mikhailova, IA | 1 |
| Faggiano, P; Gardini, A; Ghizzoni, G; Oneglia, C; Rusconi, C; Sabatini, T | 1 |
| McIsaac, W; Naylor, D | 1 |
| Guptha, S | 1 |
| Boccuzzi, SJ; Gilbert, SP; Talley, JD; Weintraub, WS | 1 |
| Nigg, C | 1 |
| Wilson, CS | 1 |
| Camrud, AR; Edwards, WD; Holmes, DR; Jorgenson, MA; Schwartz, RS; Veinot, JP | 1 |
| Lewis, LS | 1 |
| Cavero, PG; Hartzler, GO; Kacich, RL; Kahn, J; Ligon, R; Maddex, C; McCallister, BD; O'Keefe, JH; Stone, GW | 1 |
| Vandenbroucke, JP; Westendorp, RG | 1 |
| Berg, K; Faergeman, O; Haghfelt, T; Jönsson, B; Kjekshus, J; Miettinen, T; Olsson, AG; Pedersen, TR; Pyörälä, K; Schwartz, JS; Thorgeirsson, G; Wedel, H; Wilhelmsen, L | 1 |
| Holme, I | 1 |
| Windler, E | 1 |
| Grundy, SM; Mazzaferri, EL | 1 |
| Brügemann, J; Crijns, HJ; de Graeff, PA; May, JF; van Boven, AJ | 1 |
| Boccuzzi, SJ; Ghazzal, ZM; King, SB; Klein, L; Kosinski, AS; Waksman, R; Weintraub, WS | 1 |
| Pedersen, TR; Tobert, JA | 1 |
| Wray, R | 1 |
| Bjerve, KS; Carlsen, SM; Følling, I; Rossvoll, O | 1 |
| Clem, JR | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Johannesson, M; Jönsson, B; Kjekshus, J; Olsson, AG; Pedersen, TR; Wedel, H | 2 |
| Northridge, D; Wright, R | 1 |
| Foo, JI; Mamotte, CD; Sturm, M; Taylor, RR; van Bockxmeer, FM | 1 |
| Berg, K; Cook, TJ; Faergeman, O; Haghfelt, T; Kjekshus, J; Miettinen, T; Musliner, TA; Olsson, AG; Pedersen, TR; Pyörälä, K; Thorgeirsson, G; Tobert, JA; Wedel, H; Wilhelmsen, L | 1 |
| Gaw, A | 1 |
| Rackley, CE | 1 |
| Aumont, MC; Seknadji, P | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Jackson, PR; Payne, JN; Pickin, DM; Ramsay, LE; Ul Haq, I; Yeo, WW | 1 |
| Athyros, VG; Boudoulas, H; Hatzikonstandinou, HA; Kontopoulos, AG; Mayroudi, MC; Papageorgiou, AA | 1 |
| Allred, E; Andrews, TC; Barry, J; Ganz, P; Naimi, CL; Raby, K; Selwyn, AP | 1 |
| Benesch, L; Bestehorn, HP; Betz, P; Blümchen, G; Claus, J; Kappenberger, L; Mathes, P; Neiss, A; Rensing, UF; Roskamm, H; Schemeitat, K; Wieland, H | 1 |
| Armitage, JM; Collins, R; Lawson, A; Meade, TW; Mitropoulos, KA; Peto, R; Reeves, BE; Wallendszus, KR; Wilson, SS | 1 |
| Haffner, SM | 1 |
| Faergeman, O; Kjekshus, J; Olsson, AG; Pedersen, TR; Pyŏrälä, K; Thorgeirsson, G | 1 |
| Fitzsimon, C; Leclerc, C; Rivière, M; Tretiak, R; Wang, S | 1 |
| Azen, SP; Dunn, M; Hodis, HN; Mack, WJ | 1 |
| Applegate, WB; Cushman, W; Elam, MB; Heimberg, M | 1 |
| Dujovne, CA | 1 |
| Avery, BR | 1 |
| Byington, RP; Crouse, JR; Furberg, CD; Hoen, HM | 1 |
| Bhatnagar, D | 1 |
| Assmann, G | 1 |
| Crepaldi, G | 1 |
| Pauciullo, P | 1 |
| Malminiemi, K; Metsä-Ketelä, T; Palomäki, A | 1 |
| Campeau, L; Canner, PL; Geller, N; Knatterud, GL; Thompson, B; Zucker, D | 1 |
| Agner, E; Leth, A; Mortensen, SA; Rohde, M | 1 |
| Grundy, SM | 2 |
| Meiser, B; Nagel, D; Reichart, B; Seidel, D; Steinbeck, G; Thiery, J; von Scheidt, W; Wenke, K | 1 |
| Malik, AZ; Vlay, SC | 1 |
| Grover, S; Hamilton, VH; Lavoie, F; Perreault, S | 1 |
| Boccuzzi, SJ; Klein, JL; Kosinski, AS; Roehm, JB; Weintraub, WS | 1 |
| Albers, JJ; Brown, BG; Brunzell, JD; Davis, JW; Maher, VM; Poulin, D; Rocha, A; Zambon, A | 1 |
| De Caterina, R; Lenzi, S | 1 |
| Albers, J; Brown, BG; Chait, A; Cheung, M; DeAngelis, D; Dowdy, A; Fisher, LD; Frohlich, J; Heise, N; Zhao, XQ | 1 |
| Evans, MF; Por, CP; Sabharwal, M | 1 |
| Beere, PA; Clearfield, M; Downs, JR; Gotto, AM; Kruyer, W; Langendorfer, A; Shapiro, DR; Stein, EA; Weis, S; Whitney, E | 1 |
| Rosenson, RS; Tangney, CC | 1 |
| Mabuchi, H | 1 |
| Malminiemi, K; Malminiemi, O; Palomäki, A; Solakivi, T | 1 |
| Carek, PJ; MacFarlane, LL | 1 |
| Davignon, J; Farnier, M | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Otto, C; Schwandt, P | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Hunninghake, DB | 1 |
| Haq, IU; Jackson, PR; Ramsay, LE; Wallis, EJ; Yeo, WW | 1 |
| Krut, LH | 1 |
| Freemantle, N; Mason, JM | 1 |
| Goldschmidt-Clermont, PJ; Kandzari, DE | 1 |
| Hensel, WA; McDiarmid, TD | 1 |
| Mikhailidis, DP; Papadakis, JA | 1 |
| Walsh, J | 1 |
| Siegel, D; Swislocki, AL | 1 |
| Gordon, BR; Saal, SD | 1 |
| Chrisp, P; Lewis, NJ; Milne, RJ | 1 |
| Oster, G; Thompson, D | 1 |
| Hjalte, K; Lindgren, B; Persson, U | 1 |
| Reckless, JP | 1 |
| Barradell, LB; Goa, KL; McTavish, D | 1 |
| Bachman, KH | 1 |
| Herrington, DM; Morgan, TM; Pusser, BE; Riley, WA; Werbel, BL | 1 |
| de Feyter, PJ | 1 |
| Menotti, A; Poli, A | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM | 1 |
| Faulkner, MA; Hilleman, DE; Lucas, BD; Wadibia, EC | 1 |
| Smith, SC | 1 |
| Abdella, N; Akanji, AO; Mojiminiyi, OA | 1 |
| Brown, AS | 1 |
| Fruchart, JC | 1 |
| Browner, WS; Grady, D; Hulley, SB | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Granlie, C; Ijem, J | 1 |
| Davidson, MH | 1 |
| Cheng, JW; Sotiriou, CG | 1 |
| Brown, BG; Brunzell, JD; Deeb, SS; Hokanson, JE; Zambon, A | 1 |
| Gorman, C | 1 |
| Malminiemi, K; Malminiemi, O; Palomäki, A | 1 |
| Crouch, MA | 1 |
| Bergeron, J; Frohlich, J; Sniderman, AD | 1 |
| Durlach, V | 1 |
| Cantin, B; Dagenais, GR; Després, JP; Lamarche, B; Sniderman, AD | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Goto, Y | 1 |
| Sprecher, DL | 1 |
| Gaw, A; Pedersen, T | 1 |
| Waters, DD | 1 |
| Kalmansohn, RB; Kalmansohn, RW; Schiff, DL | 1 |
| Ferns, GA | 1 |
| Clearfield, M; Downs, JR; Gotto, AM; Miles, JS; Ridker, PM; Rifai, N; Weis, SE | 1 |
| Munford, RS | 1 |
| Budoff, MJ; Raggi, P | 1 |
| Bruckert, E | 1 |
| Susekov, AV | 1 |
| Auer, J; Eber, B | 1 |
| McCarey, DW; McInnes, IB; Sattar, N | 1 |
| McCullough, PA | 1 |
| Werkö, L | 1 |
| Platts, J | 1 |
| Ali, SI; Asker, ME; El-Swefy, SE; Mohammed, HE | 1 |
| Stein, EA | 1 |
| Clearfield, M; Cook, TJ; Downs, JR; Gotto, AM; Pradhan, AD; Ridker, PM; Shih, J; Weis, SE | 1 |
| Goldbourt, U; Graff, E; Koren-Morag, N; Tanne, D | 1 |
| Taskinen, MR | 1 |
| Seed, M | 1 |
| Pekkanen, J; Smith, GD | 1 |
| Becker, PJ; Firth, J; Marais, AD; Ubbink, JB; Ungerer, JP; Van Lathem, JM; Vermaak, WJ | 1 |
| Baranova, TA; Nikitina, VI; Safiullina, ZM; Shalaev, SV; Zhuravleva, TD | 1 |
| Kacharava, AG; Orekhov, AN; Tertov, VV; Zhukova, IM | 1 |
| Fooks, T; Tavare, S | 1 |
| Arndtz, N; Meiser, BM; Reichart, B; Seidel, D; Thiery, J; Wenke, K | 1 |
| Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW | 1 |
| Tobert, JA | 1 |
| Marchant, B | 1 |
| Alexander, RW; Boccuzzi, SJ; Brown, CL; Cohen, CL; Hirsch, LJ; King, SB; Weintraub, WS | 1 |
| Beigel, Y; Davidson, E; Fuchs, J; Green, P; Rotenberg, Z; Weinberger, I; Zlotikamien, B | 1 |
| Kukharchuk, V; Martinov, A; Pomerantsev, E; Shabalkin, B; Titov, V; Yurenev, A; Zhukova, I | 1 |
| Goldman, L; Goldman, PA; Weinstein, MC; Williams, LW | 1 |
| Gotto, AM; Hay, JW; Wittels, EH | 1 |
| Partanen, J | 1 |
| Groskop, I; Lurie, Y; Rubinstein, A; Weintrob, M | 1 |
| Bocanegra, TS; Boccuzzi, SJ; Keegan, ME; Shapiro, DR; Walker, JF | 1 |
| Bain, SC; Jones, AF; Lemon, M; Walker, MR | 1 |
| Banka, VS; Maniet, AR; Sahni, R; Voci, G | 1 |
| Ascoop, CA; Erkelens, DW; Martens, LL; Rutten, FF | 2 |
| Thompson, WG | 1 |
| Jones, PH | 1 |
| Albers, JJ; Bisson, BD; Brown, G; Dodge, HT; Fisher, LD; Fitzpatrick, VF; Kaplan, C; Lin, JT; Schaefer, SM; Zhao, XQ | 1 |
| Folkers, K; Langsjoen, P; Richardson, P; Tamagawa, H; Willis, R; Xia, LJ; Ye, CQ | 1 |
| Bochkova, EI; Iurenev, AP; Kotkina, AA; Lediashova, GA; Martynov, AA; Pomerantsev, EV; Shabalkin, BV; Shimbaeva, NA; Titov, VN; Zhukova, IM | 1 |
| French, J; White, H | 1 |
| French, JK; Greaves, SC; White, HD | 1 |
| Armstrong, V; Bosch, T; Eisenhauer, T; Schuff-Werner, P; Seidel, D; Thiery, J | 1 |
| Iurenev, AP; Kiseleva, OA; Lediashova, GA; Pomerantsev, EV; Zhukova, IM | 1 |
| Fusman, B; Lefer, AM; Lento, PH; Osborne, JA; Siegfried, MR; Stahl, GL | 1 |
| Garg, A; Grundy, SM | 2 |
| Alig, J; Stacpoole, PW | 1 |
| Brewer, HB; Hoeg, JM; Starzl, TE | 1 |
| Gordon, DJ; Rifkind, BM | 1 |
63 review(s) available for lovastatin and Coronary Heart Disease
| Article | Year |
|---|---|
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Update on the management of dyslipidemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Assessment; Risk Factors | 2002 |
Management of dyslipidemia in the primary prevention of coronary heart disease.
Topics: Animals; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2002 |
[Primary and secondary prevention of coronary disease by statins].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1999 |
Lovastatin extended release: a review of its use in the management of hypercholesterolaemia.
Topics: Absorption; Administration, Oral; Anticholesteremic Agents; Coronary Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Lovastatin | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Optimal goals for statin use in patients with coronary artery disease.
Topics: Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Treatment Outcome | 2005 |
Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Research Design; Risk Assessment; Risk Factors; Treatment Outcome | 2007 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides | 1984 |
New strategies in the development of anti-atherosclerotic drugs.
Topics: 4-Aminobenzoic Acid; Animals; Arteriosclerosis; Aspirin; Coronary Disease; Fatty Acids, Nonesterified; Hepatomegaly; Humans; Hydrogen Peroxide; Hypolipoproteinemias; Lovastatin; Male; Metformin; Microbodies; Naphthalenes; Oligopeptides; para-Aminobenzoates; Platelet Aggregation; Rats | 1980 |
Angiographic trials of lipid-lowering therapy: end of an era?
Topics: Adult; Clinical Trials as Topic; Coronary Angiography; Coronary Disease; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Extending the benefit of lipid-regulating therapy to primary prevention.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic | 1995 |
Statins: is there a need for alternative or adjunctive therapy?
Topics: Anticholesteremic Agents; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Simvastatin | 1995 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Graft vessel disease: the impact of immunosuppression and possible treatment strategies.
Topics: Animals; Coronary Disease; Graft Rejection; Heart Transplantation; Immunosuppressive Agents; Interferon-gamma; Lovastatin; Male; Oligopeptides; Peptides, Cyclic; Rats; Rats, Inbred BN; Rats, Inbred Lew; Simvastatin; Somatostatin | 1993 |
Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications.
Topics: Angiography; Clinical Trials as Topic; Colestipol; Coronary Disease; Humans; Hypercholesterolemia; Lipids; Lovastatin; Niacin; Random Allocation | 1994 |
Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Calcium Channel Blockers; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Fish Oils; Humans; Lovastatin; Methylprednisolone; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence | 1993 |
The 4S study. Implications for prescribing.
Topics: Anticholesteremic Agents; Cholesterol; Controlled Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diet; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Longitudinal Studies; Lovastatin; Simvastatin | 1996 |
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Topics: Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin | 1996 |
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Topics: Carotid Artery Diseases; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 1996 |
Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Simvastatin; Survival Analysis | 1996 |
Reductase inhibitor monotherapy and stroke prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Longevity; Lovastatin; Niacin; Simvastatin | 1997 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss | 1998 |
Use of niacin, statins, and resins in patients with combined hyperlipidemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Cohort Studies; Colestipol; Coronary Disease; Drug Therapy, Combination; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Niacin; Risk Factors; Triglycerides | 1998 |
[Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diet; Endothelium, Vascular; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Mevalonic Acid; Middle Aged; Physical Exertion; Primary Prevention; Simvastatin; Time Factors | 1998 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Current and future treatment of hyperlipidemia: the role of statins.
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Are there differences in various statins?].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Postoperative Period; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
Topics: Adult; Aged; Coronary Disease; Costs and Cost Analysis; Drug Prescriptions; Drug Tolerance; Economics, Pharmaceutical; Female; Formularies as Topic; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Primary Prevention; Risk Factors | 1992 |
Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.
Topics: Age Factors; Cholestyramine Resin; Colestipol; Coronary Disease; Cost-Benefit Analysis; Humans; Hypercholesterolemia; Lovastatin; Risk Factors; Sex Factors; Treatment Outcome | 1992 |
Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
Topics: Coronary Disease; Cost-Benefit Analysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1997 |
[Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Smoking; Time Factors | 1999 |
Bridging the treatment gap.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Self Medication; Simvastatin; United States | 2000 |
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Risk Factors; Simvastatin | 2000 |
More than cholesterol: the complexity of coronary artery disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Disease Progression; Endothelium; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Risk Factors | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.
Topics: Blood Coagulation; Blood Platelets; Blood Pressure; Blood Viscosity; Cholesterol; Coronary Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth; Pravastatin; Simvastatin | 2000 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
[Statins: intervention studies, facts and perspectives].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Infarction; Stroke | 2001 |
[AFCAPS/TexCAPS [The Air Force/Texas Coronary Atherosclerosis Prevention Study]].
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Texas; Treatment Outcome | 2001 |
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Myocardial Infarction; Niacin; Ultrasonography | 2000 |
Statins--similarities and differences.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Structure-Activity Relationship; United States | 2001 |
What do the statin trials tell us?
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Outcome Assessment, Health Care; Pravastatin; Stroke; United States | 2001 |
Coronary artery disease progression assessed by electron-beam computed tomography.
Topics: Calcinosis; Coronary Disease; Humans; Hypolipidemic Agents; Lovastatin; Reproducibility of Results; Tomography, X-Ray Computed | 2001 |
[Therapeutic and pleiotropic effects of statins in primary and secondary prevention of atherosclerosis].
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Drug Therapy, Combination; Humans; Lovastatin; Research | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Diabetic dyslipidemia.
Topics: Apolipoproteins; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Lovastatin; Prevalence; Risk Factors | 2002 |
The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women.
Topics: Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lovastatin; Postmenopause; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors | 2002 |
Hyperlipidemia and transplantation: etiologic factors and therapy.
Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Coronary Disease; Diuretics; Gemfibrozil; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lipid Metabolism; Lipoprotein Lipase; Lovastatin; Postoperative Complications; Risk Factors | 1992 |
Cholesterol: myth or reality?
Topics: Age Factors; Aged; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Evaluation Studies as Topic; Female; Follow-Up Studies; Health Education; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Reference Values; Risk Factors; Sex Factors | 1990 |
Lovastatin and simvastatin prevention studies.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1990 |
Advances in the treatment of coronary heart disease: fish oils, cholestyramine, and mevinolin.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Dietary Fats, Unsaturated; Enterohepatic Circulation; Fatty Acids, Unsaturated; Fish Oils; Humans; Ion Exchange Resins; Lipid Metabolism; Lovastatin; Male; Middle Aged; Naphthalenes | 1987 |
77 trial(s) available for lovastatin and Coronary Heart Disease
| Article | Year |
|---|---|
Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Postoperative Care; Prospective Studies; Treatment Outcome | 2008 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study).
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models | 2005 |
Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts.
Topics: Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Disease Progression; Female; Graft Occlusion, Vascular; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Prognosis; Prospective Studies; Risk Factors; Sensitivity and Specificity; Smoking; Warfarin | 2006 |
Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Colchicine; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Enalapril; Female; Humans; Lovastatin; Male; Middle Aged; Pilot Projects; Recurrence | 1995 |
[The Scandinavian Simvastatin Survival Study: the clinical consequences].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Scandinavian and Nordic Countries; Simvastatin; Survivors | 1995 |
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Infarction; Risk Factors; Scandinavian and Nordic Countries; Sex Factors; Simvastatin; Survival Rate | 1995 |
[The simvastatin study--was the consumption of wine considered?].
Topics: Alcohol Drinking; Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin; Wine | 1995 |
[Real results of The Scandinavian Simvastatin Survival Study (4S)].
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Lovastatin; Male; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[The Scandinavian Simvastatin Survival Study (4S): hasty conclusions].
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Lovastatin; Male; Scandinavian and Nordic Countries; Simvastatin | 1995 |
The effect of lovastatin on early restenosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Double-Blind Method; Exercise Test; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Prospective Studies; Recurrence | 1995 |
Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study.
Topics: Adult; Colestipol; Coronary Disease; Diet, Fat-Restricted; Humans; Lovastatin; Male; Middle Aged; Niacin | 1995 |
[Unfortunate presentation of statin therapy in the mass media].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Mass Media; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Simvastatin decreases mortality.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Middle Aged; Simvastatin; Treatment Outcome | 1995 |
[The Scandinavian Simvastatin Survival Study (4S)].
Topics: Anticholesteremic Agents; Coronary Disease; Drug Evaluation; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1995 |
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Niacin; Patient Selection; Prospective Studies; Risk Factors; Treatment Outcome | 1995 |
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Lovastatin; Male; Middle Aged; Risk; Simvastatin | 1995 |
Is a reduction of graft vessel disease by maximal treatment of hypercholesterolemia after heart transplantation possible?
Topics: Adult; Coronary Disease; Cyclosporine; Female; Graft Occlusion, Vascular; Graft Rejection; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
[The Scandinavian Simvastatin Survival Study].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Lovastatin; Male; Middle Aged; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[Statin prevents coronary disease. The 4S study changes the therapeutic practice].
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[The 4S study is convincing--without explanation].
Topics: Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Endothelium, Vascular; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
Topics: Angioplasty, Balloon, Coronary; Cholesterol, HDL; Coronary Angiography; Coronary Disease; Double-Blind Method; Female; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Prospective Studies; Recurrence; Treatment Outcome | 1994 |
Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Liver Function Tests; Lovastatin; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1994 |
Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diuretics; Drug Tolerance; Female; Humans; Hypercholesterolemia; Hypertension; Lovastatin; Male; Middle Aged; Retrospective Studies; Time Factors; Triglycerides | 1993 |
Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, LDL; Colestipol; Coronary Angiography; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Niacin; Treatment Outcome | 1994 |
Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Belgium; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Double-Blind Method; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ireland; Lovastatin; Netherlands; Recurrence; Research Design; Spain; Time Factors; United Kingdom | 1994 |
[Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Drug Tolerance; Fatty Acids, Omega-3; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
Topics: Adult; Aged; Cholesterol, Dietary; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Coronary Vessels; Double-Blind Method; Female; Humans; Lipids; Lovastatin; Male; Middle Aged | 1993 |
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B.
Topics: Adult; Apolipoproteins B; Colestipol; Coronary Disease; Coronary Vessels; Double-Blind Method; Exercise Test; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Radiography | 1993 |
[Lovastatin in the treatment of hypercholesterolemia in non-insulin-dependent diabetes mellitus patients].
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged | 1993 |
Costs of coronary restenosis (Lovastatin Restenosis Trial).
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Prospective Studies; Radiography; Recurrence; Treatment Outcome | 1996 |
Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Constriction, Pathologic; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lipoproteins; Lovastatin; Male; Middle Aged; Probucol; Recurrence | 1996 |
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Double-Blind Method; Female; Health Care Costs; Humans; Lovastatin; Male; Middle Aged; Simvastatin | 1996 |
[Statin therapy of individuals with high risk for coronary disease].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Male; Pravastatin; Risk Factors; Scotland; Simvastatin | 1996 |
[A new study on hypercholesterolemia. Statin is effective against heart disease].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Lovastatin; Male; Middle Aged; Pravastatin; Scandinavian and Nordic Countries; Scotland; Simvastatin | 1996 |
Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
Topics: Blood Glucose; Body Weight; Combined Modality Therapy; Coronary Disease; Diet; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Lipids; Lovastatin; Male; Metformin; Middle Aged; Prospective Studies | 1996 |
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Simvastatin | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Topics: Adult; Analysis of Variance; Clofibric Acid; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fibric Acids; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Morbidity; Prospective Studies; Safety; Simvastatin; Survival Rate; Treatment Outcome; Ultracentrifugation | 1996 |
Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Diet; Electrocardiography; Female; Humans; Lovastatin; Male; Middle Aged; Myocardial Ischemia | 1997 |
The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Treatment Outcome | 1997 |
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Topics: Adult; Aged; Chromatography, Thin Layer; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Factor VII; Factor XII; Fatty Acids, Nonesterified; Female; Fibrinogen; Follow-Up Studies; Hemostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Prospective Studies; Prothrombin; Risk Factors; Simvastatin; Single-Blind Method | 1997 |
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Placebos; Prognosis; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Time Factors; Triglycerides | 1997 |
Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
Topics: Aged; Canada; Coronary Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Health Resources; Health Services Research; Humans; Hypolipidemic Agents; Lovastatin; Middle Aged; Models, Economic; Prognosis; Simvastatin; Survival Analysis; Time Factors | 1997 |
A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Computers; Coronary Angiography; Coronary Disease; Data Interpretation, Statistical; Disease Progression; Double-Blind Method; Female; Humans; Lovastatin; Male; Observer Variation; Predictive Value of Tests; Reproducibility of Results; Research Design | 1997 |
Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Copper; Coronary Disease; Cross-Over Studies; Double-Blind Method; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Triglycerides; Ubiquinone; Vitamin E | 1997 |
An application of the Zucker-Wittes modified ratio estimate statistic in the Post Coronary Artery Bypass Graft (CABG) clinical trial.
Topics: Anticholesteremic Agents; Anticoagulants; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Data Interpretation, Statistical; Double-Blind Method; Follow-Up Studies; Humans; Lovastatin; Saphenous Vein; Warfarin | 1997 |
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
Topics: Adult; Aged; Antioxidants; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coenzymes; Coronary Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Risk Factors; Ubiquinone | 1997 |
Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Disease; Echocardiography; Female; Graft Rejection; Heart Transplantation; Humans; Incidence; Lovastatin; Male; Middle Aged; Mortality; Postoperative Complications; Prospective Studies; Simvastatin; Survival Analysis | 1997 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diet, Fat-Restricted; Double-Blind Method; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Proportional Hazards Models; Reference Values; Risk Factors; Triglycerides | 1998 |
Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo.
Topics: Analysis of Variance; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Copper Sulfate; Coronary Disease; Cross-Over Studies; Diet; Double-Blind Method; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Oxidative Stress; Triglycerides; Ubiquinone | 1998 |
When the vessel is bad, lowering cholesterol may save the ship.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Denmark; Evidence-Based Medicine; Female; Humans; Hypercholesterolemia; Iceland; Lovastatin; Male; Middle Aged; Mortality; Norway; Sweden; Treatment Outcome | 1997 |
Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Lovastatin; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone Congeners; Retrospective Studies; Treatment Outcome; Vasodilation | 1999 |
Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Male; Middle Aged; Military Personnel; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk; Risk Factors; Sex Factors; Smoking; Texas; Treatment Outcome | 1999 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial.
Topics: Aged; Cholesterol; Colestipol; Coronary Disease; Counseling; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Patient Compliance; Pharmacists; Time Factors; Treatment Outcome; Triglycerides | 2000 |
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
Topics: Analysis of Variance; Cholesterol, HDL; Colestipol; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Genotype; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Lovastatin; Male; Middle Aged; Niacin; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Regression Analysis | 2001 |
Comparison of LDL trap assay to other tests of antioxidant capacity; effect of vitamin E and lovastatin treatment.
Topics: Amidines; Anticholesteremic Agents; Antioxidants; Copper Sulfate; Coronary Disease; Cross-Over Studies; Double-Blind Method; Humans; Hyperlipidemias; Lipoproteins, LDL; Lovastatin; Male; Oxidants; Oxidation-Reduction; Reproducibility of Results; Sensitivity and Specificity; Vitamin E | 2000 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
Topics: Acute Disease; Anticholesteremic Agents; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Primary Prevention; Proportional Hazards Models; Risk; Risk Factors | 2001 |
Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.
Topics: Acute Disease; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Homocysteine; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Risk Factors | 2002 |
Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry.
Topics: Adult; Aged; Bezafibrate; Brain Ischemia; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Disease; Follow-Up Studies; Humans; Hypolipidemic Agents; Ischemic Attack, Transient; Lovastatin; Middle Aged; Multivariate Analysis; Odds Ratio; Registries; Risk Factors; Survival Analysis; Time Factors | 2002 |
[Effects of lovastatin therapy on the level of low density lipoproteins and atherogenic potential of serum in patients with ischemic heart disease and hypercholesterolemia].
Topics: Animals; Antigen-Antibody Complex; Cells, Cultured; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Macrophages; Mice | 1992 |
Treatment of hypercholesterolemia and prevention of coronary artery disease after heart transplantation by combination of low-dose simvastatin and HELP-LDL-apheresis.
Topics: Adult; Anticholesteremic Agents; Blood Component Removal; Chemical Precipitation; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1992 |
Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty. The Lovastatin Restenosis Trial Study Group.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Humans; Lovastatin; Recurrence | 1992 |
Big platelets in hyperlipidemic patients.
Topics: Aged; Blood Platelets; Coronary Disease; Double-Blind Method; Female; Fish Oils; Humans; Hyperlipidemias; Infant, Newborn; Lovastatin; Male; Middle Aged; Risk Factors; Triglycerides | 1992 |
Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II.
Topics: Adult; Aged; Angina Pectoris; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Exercise Test; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged | 1992 |
Long-term safety and efficacy profile of simvastatin.
Topics: Aged; Anticholesteremic Agents; Cataract; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Liver; Lovastatin; Male; Middle Aged; Muscles; Simvastatin | 1991 |
Prevention of restenosis by lovastatin after successful coronary angioplasty.
Topics: Angiography; Angioplasty, Balloon, Coronary; Cholesterol; Coronary Disease; Electrocardiography; Exercise Test; Follow-Up Studies; Humans; Lovastatin; Postoperative Care; Radionuclide Imaging; Recurrence; Thallium | 1991 |
Cholesterol: myth or reality?
Topics: Age Factors; Aged; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Evaluation Studies as Topic; Female; Follow-Up Studies; Health Education; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Reference Values; Risk Factors; Sex Factors | 1990 |
Lovastatin and simvastatin prevention studies.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1990 |
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coronary Disease; Diet; Double-Blind Method; Drug Therapy, Combination; Humans; Lovastatin; Male; Middle Aged; Multivariate Analysis; Niacin | 1990 |
Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin.
Topics: Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Random Allocation | 1988 |
Advances in the treatment of coronary heart disease: fish oils, cholestyramine, and mevinolin.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Dietary Fats, Unsaturated; Enterohepatic Circulation; Fatty Acids, Unsaturated; Fish Oils; Humans; Ion Exchange Resins; Lipid Metabolism; Lovastatin; Male; Middle Aged; Naphthalenes | 1987 |
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Triglycerides | 1988 |
132 other study(ies) available for lovastatin and Coronary Heart Disease
| Article | Year |
|---|---|
Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genetic Association Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver-Specific Organic Anion Transporter 1; Lovastatin; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Risk Assessment; Simvastatin | 2015 |
Influence of drug treatment on glucocorticoid receptor levels in patients with coronary heart disease.
Topics: Aged; Blotting, Western; Coronary Disease; Female; Humans; Isosorbide Dinitrate; Lovastatin; Male; Metoprolol; Middle Aged; Nifedipine; Receptors, Glucocorticoid | 2010 |
Lipid-lowering therapy after coronary artery bypass grafting: time for more aggressive intervention.
Topics: Colestipol; Coronary Artery Bypass; Coronary Disease; Humans; Hypolipidemic Agents; Lovastatin; Patient Compliance; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
[Treatment with statins: further data from the Heart Protection Study].
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Female; Humans; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2002 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
[The "healthy" patient with hypercholesterolemia].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Geriatric Assessment; Health Status; Humans; Hypercholesterolemia; Hypertension; Lipoprotein(a); Lovastatin; Practice Guidelines as Topic; Risk Factors | 2005 |
Potential impact on cardiovascular public health of over-the-counter statin availability.
Topics: Blood Pressure; Cholesterol; Coronary Disease; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Lovastatin; Nonprescription Drugs; Public Health; Risk Factors; Treatment Outcome | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Military Personnel; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Texas; Time Factors; Treatment Outcome; Triglycerides | 2007 |
A new perspective on nonprescription statins: an opportunity for patient education and involvement.
Topics: Anticholesteremic Agents; Coronary Disease; Health Education; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nonprescription Drugs; Patient Education as Topic; Patient Participation; Primary Prevention; Risk Assessment; Safety; Treatment Outcome | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cohort Studies; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Diseases; Liver Function Tests; Lovastatin; Male; Middle Aged; Retrospective Studies; Risk Assessment | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Cholesterol--heart disease link illuminated. New findings explain how blood cholesterol levels are controlled and how to lower them substantially in persons at high risk of heart disease.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Naphthalenes; Rabbits; Receptors, Cell Surface; Receptors, LDL | 1983 |
Statins prevent coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1995 |
Management of patients with dyslipidaemia.
Topics: Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1995 |
Lowering patients' cholesterol. Extrapolating results of trial of simvastatin gives room for doubt.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Lovastatin; Risk Factors; Simvastatin | 1995 |
[Is treatment of hypercholesterolemia able to reduce total mortality?].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Cohort Studies; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Randomized Controlled Trials as Topic; Risk; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Doctors, research funds and marketing.
Topics: Advertising; Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1995 |
Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Cost Savings; Drug Costs; Drug Monitoring; Fatty Acids, Monounsaturated; Fluvastatin; Hospitals, Veterans; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; New York; Primary Prevention; Treatment Outcome; United States; United States Department of Veterans Affairs | 1995 |
Can aggressive efforts directed at lipid lowering post-PTCA reduce the risk of restenosis?
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Humans; Lovastatin; Recurrence | 1995 |
Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston.
Topics: Aged; Anticholesteremic Agents; Aspirin; beta Carotene; Carotenoids; Cholesterol, Dietary; Coronary Disease; Diet, Fat-Restricted; Diltiazem; Drug Therapy, Combination; Enalapril; Humans; Lovastatin; Male; Simvastatin; Tomography, Emission-Computed; Vitamins | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Combined Modality Therapy; Coronary Disease; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
[Unfortunate report on simvastatin therapy in the mass media].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Mass Media; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Cholesterol-lowering, simvastatin, and coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Simvastatin; Survival Rate | 1995 |
Reversing risk in coronary disease.
Topics: Arteriosclerosis; Carotid Artery Diseases; Coronary Disease; Humans; Lovastatin | 1995 |
Cholesterol lowering does have a role in secondary prevention.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Diet; Humans; Life Style; Lovastatin; Middle Aged; Simvastatin | 1995 |
Cholesterol hypothesis vindicated by simvastatin study. Why did it take so long?
Topics: Animals; Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1995 |
Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis.
Topics: Adenine; Cell Division; Cells, Cultured; Cholesterol; Coronary Disease; Farnesol; Humans; Isopentenyladenosine; L-Lactate Dehydrogenase; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Saphenous Vein | 1994 |
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Topics: Adult; Age Factors; Aged; Canada; Cholesterol, HDL; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Lovastatin; Male; Middle Aged; Models, Theoretical; Sex Factors; United States; Value of Life | 1995 |
Dropping cholesterol--safely.
Topics: Cholesterol; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1994 |
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician.
Topics: Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Niacin | 1994 |
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia.
Topics: Adult; Biopsy; Cells, Cultured; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Gene Expression Regulation; Genes, Synthetic; Genetic Therapy; Genetic Vectors; Humans; Hyperlipoproteinemia Type II; In Situ Hybridization, Fluorescence; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Lovastatin; Receptors, LDL; Recombinant Proteins; Safety; Up-Regulation | 1994 |
Effects of lovastatin and pravastatin on coronary artery disease.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic | 1994 |
Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation.
Topics: Adult; Anticholesteremic Agents; Cholesterol, Dietary; Cholesterol, LDL; Coronary Disease; Female; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin; Survival Analysis | 1994 |
Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids.
Topics: Adult; Cholesterol; Coronary Disease; Drug Therapy, Combination; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Phosphatidylcholines; Platelet Aggregation | 1993 |
[Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Risk Factors; Severity of Illness Index; Simvastatin | 1993 |
HMGCoA reductase inhibitors.
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male | 1993 |
Beneficial effects of simvastatin may be due to non-lipid actions.
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Humans; Lovastatin; Simvastatin | 1995 |
Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study.
Topics: Adult; Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diet Therapy; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1995 |
[The 4-S study--a turning point in the cholesterol debate. Work Group Lipids and Atherosclerosis of the Swiss Society for Cardiology].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Treating hypercholesterolemia aggressively.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Simvastatin | 1996 |
The effects of lovastatin on neointimal hyperplasia following injury in a porcine coronary artery model.
Topics: Angioplasty, Balloon, Coronary; Animals; Coronary Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitors; Hyperplasia; Linear Models; Lovastatin; Random Allocation; Recurrence; Single-Blind Method; Swine; Tunica Intima | 1996 |
Statins, cholesterol, and mevalonate pathways?
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Mevalonic Acid; Simvastatin | 1996 |
Are the effects of cholesterol lowering drugs always equal?
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Male; Simvastatin | 1996 |
[Current developments in prevention of coronary heart disease].
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Survival Rate | 1996 |
Addressing the spectrum of hypercholesterolemia.
Topics: Adult; Aged; Algorithms; Anticholesteremic Agents; Coronary Disease; Diet, Fat-Restricted; Exercise; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin; Smoking Cessation | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Constriction, Pathologic; Coronary Disease; Humans; Lovastatin; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 1996 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Coronary Disease; Diet; Factor VII; Humans; Hyperlipidemias; Lovastatin; Risk Factors; Simvastatin; Smoking | 1995 |
Improved survival with statin therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
Topics: Anticholesteremic Agents; Case-Control Studies; Clinical Trials as Topic; Coronary Disease; Cost of Illness; Cost-Benefit Analysis; Evaluation Studies as Topic; Humans; Hypercholesterolemia; Lovastatin; Prospective Studies; Reproducibility of Results; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1996 |
Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Binding, Competitive; Cells, Cultured; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Receptors, LDL; Simvastatin; Triglycerides | 1996 |
The statin trials: closing arguments in the case against cholesterol?
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin | 1996 |
Lipid-lowering for prevention of coronary heart disease: what policy now?
Topics: Adult; Age Factors; Aged; Cholesterol; Coronary Disease; Costs and Cost Analysis; Female; Health Policy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Risk; Simvastatin; United Kingdom | 1996 |
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Markov Chains; Middle Aged; Proportional Hazards Models; Sex Factors; Simvastatin; Value of Life | 1997 |
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Diabetic Angiopathies; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Triglycerides | 1997 |
Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Enzyme Inhibitors; Female; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Morbidity; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Simvastatin | 1997 |
The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study.
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Simvastatin | 1997 |
Treatment of the patient with primary familial heterozygous hypercholesterolemia.
Topics: Aged; Colestipol; Coronary Disease; Diet, Fat-Restricted; Drug Therapy, Combination; Exercise; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Weight Loss | 1995 |
Stain therapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Simvastatin | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Myocardial Infarction; Pravastatin; Simvastatin | 1997 |
Simvastatin in the secondary prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1997 |
The 4S study: a critical review.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1997 |
The 4S study: a critical review.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin | 1997 |
Long-term patency (9 1/2 years) and atherosclerosis of a polytetrafluoroethylene (Gortex) coronary artery bypass graft.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Blood Vessel Prosthesis; Cardiac Catheterization; Cholesterol; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Hyperlipidemias; Lovastatin; Polytetrafluoroethylene; Prosthesis Failure | 1998 |
Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Risk; United States | 1998 |
Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial).
Topics: Aged; Angioplasty, Balloon, Coronary; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 1998 |
Do statin drugs lower the risk of stroke?
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Lovastatin; Meta-Analysis as Topic; Pravastatin; Risk Factors; Simvastatin | 1998 |
Lovastatin to prevent acute coronary events with average cholesterol levels.
Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol; Coronary Disease; Death, Sudden, Cardiac; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 1998 |
[Lipid lowering: myth or therapeutic necessity?].
Topics: Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Pyridines; Risk Factors | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Risk | 1999 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin | 1999 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Lovastatin; Quality of Life; Risk | 1999 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anti-Arrhythmia Agents; Anticholesteremic Agents; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1999 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Hormone Replacement Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Platelet Aggregation Inhibitors; Risk | 1999 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Coronary Disease; Humans; Lovastatin; Melanoma | 1999 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Lovastatin; Male; Sex Factors | 1999 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Lovastatin; Survival Analysis | 1999 |
Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992.
Topics: Adult; Aged; Blood Component Removal; Child; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Dextran Sulfate; Humans; Hypercholesterolemia; Immunosorbent Techniques; Lovastatin; Middle Aged; Niacin; Pilot Projects | 1993 |
Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.
Topics: Adult; Cholestyramine Resin; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Health Care Costs; Humans; Hypercholesterolemia; Life Expectancy; Lovastatin; Male; Middle Aged; Multivariate Analysis; Sweden | 1992 |
The 4S study and its pharmacoeconomic implications.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1996 |
Lipids and coronary restenosis:an elusive link.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Female; Humans; Lipids; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 1999 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima | 2000 |
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Fasting; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Islam; Kuwait; Lipoproteins, HDL; Lovastatin; Male; Middle Aged | 2000 |
Primary prevention of coronary heart disease: implications of the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS).
Topics: Adult; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Lovastatin; Male; Military Personnel; Randomized Controlled Trials as Topic; Texas; Treatment Outcome | 2000 |
A need to redefine the consensus on the use of statins in coronary heart disease prevention.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Pravastatin | 2000 |
Statins: underused by those who would benefit.
Topics: Age Factors; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Humans; Hypolipidemic Agents; Legislation, Drug; Lovastatin; Nonprescription Drugs; Pravastatin; Self Medication; United States | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Keeping vessels clear after bypass surgery.
Topics: Anticholesteremic Agents; Anticoagulants; Coronary Artery Bypass; Coronary Disease; Humans; Lovastatin; Secondary Prevention; Warfarin | 2000 |
Are statins right for you?
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; United States | 2000 |
Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.
Topics: Apolipoproteins B; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Monitoring; Humans; Hyperlipidemias; Lovastatin; Practice Patterns, Physicians'; Predictive Value of Tests | 2001 |
High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol.
Topics: Anticholesteremic Agents; Apolipoproteins B; Body Mass Index; Cholesterol; Cholesterol, HDL; Coronary Disease; Humans; Lovastatin; Male; Middle Aged; Risk Factors; Triglycerides | 2001 |
Revised indications for statin therapies.
Topics: Cardiovascular Diseases; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lovastatin | 2001 |
The National Service Framework on coronary heart disease: is it sufficiently evidence-based?
Topics: Anticholesteremic Agents; Coronary Disease; Delivery of Health Care; Evidence-Based Medicine; Humans; Lovastatin; Phenotype; United Kingdom | 2001 |
Statins and the acute-phase response.
Topics: Acute-Phase Reaction; Anticholesteremic Agents; Arteriosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin | 2001 |
The antiinflammatory effects of statins.
Topics: Coronary Disease; Genes, MHC Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Lovastatin; Lymphocyte Function-Associated Antigen-1; Simvastatin; T-Lymphocytes | 2001 |
The antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cholesterol, LDL; Confounding Factors, Epidemiologic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Risk Factors | 2001 |
[Can the action of statins reveal etiology of coronary diseases?].
Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Humans; Lovastatin; Male; Pravastatin; Randomized Controlled Trials as Topic | 2001 |
Therapy and clinical trials.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis | 2002 |
A novel concept to preserve the beneficial effects of hormone replacement therapy in bilaterally female ovariectomized rats: role of lovastatin therapy.
Topics: Animals; C-Reactive Protein; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Estradiol; Female; Hormone Replacement Therapy; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitric Oxide; Ovariectomy; Postmenopause; Progesterone; Rats; Rats, Wistar | 2002 |
The cholesterol controversy.
Topics: Coronary Disease; Humans; Hypercholesterolemia; Lovastatin | 1992 |
Using changes in attributable risk to predict long-term efficacy of simvastatin treatment.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin | 1992 |
[Effects of lovastatin (mevacor) on platelet function in hypercholesterolemia in patients with ischemic heart disease].
Topics: Adult; Blood Platelets; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Platelet Aggregation; Time Factors | 1992 |
Coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Lovastatin; Male | 1992 |
The cholesterol controversy.
Topics: Cholesterol; Coronary Disease; Humans; Lovastatin | 1992 |
Lovastatin on restenosis.
Topics: Clinical Trials as Topic; Coronary Disease; Drug Costs; Humans; Lovastatin; Recurrence | 1992 |
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Primary Prevention; Sensitivity and Specificity | 1991 |
An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.
Topics: Adult; Age Factors; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Disability Evaluation; Evaluation Studies as Topic; Fees, Medical; Female; Humans; Hypercholesterolemia; Life Expectancy; Lovastatin; Male; Middle Aged; Risk Factors; Sensitivity and Specificity; Smoking; Value of Life | 1991 |
Economic evaluation of cholesterol lowering.
Topics: Cholesterol; Coronary Disease; Humans; Lovastatin | 1991 |
Cholesterol-lowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dl (5.18 to 6.21 mmol/liter).
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Risk Factors | 1991 |
Apolipoprotein(a) and ischaemic heart disease.
Topics: Anticholesteremic Agents; Apolipoproteins A; Coronary Disease; Heptanoic Acids; Humans; Liver; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Lovastatin; Male; Middle Aged; Netherlands; Risk Factors; Simvastatin | 1990 |
Lovastatin decreases coenzyme Q levels in humans.
Topics: Adolescent; Cardiac Output; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Contraction; Stroke Volume; Ubiquinone | 1990 |
[The effect of lovastatin therapy on the dynamics of the clinical state of patients with ischemic heart disease and hyperlipoproteinemia].
Topics: Adult; Apolipoproteins; Cholesterol; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Hyperlipoproteinemias; Lipoproteins; Lovastatin; Male; Middle Aged; Triglycerides | 1990 |
Misconceptions about cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Attitude; Cholesterol; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; New Zealand; Simvastatin | 1990 |
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Tolerance; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Simvastatin; Single-Blind Method; Triglycerides | 1990 |
[Maximal therapy of hypercholesterolemia in coronary heart disease].
Topics: Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Plasma Exchange; Simvastatin | 1990 |
Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine.
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Lovastatin; Male; Middle Aged; Netherlands; Simvastatin | 1989 |
[The effectiveness of the hypolipemic preparation lovastatin in patients with ischemic heart disease and hyperlipoproteinemia].
Topics: Adult; Chronic Disease; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged | 1989 |
Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment.
Topics: Animals; Cardiovascular System; Cholesterol, Dietary; Coronary Disease; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isoenzymes; Lovastatin; Male; Myocardium; Rabbits | 1989 |
Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia.
Topics: Child; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Transplantation; Lovastatin; Male; Naphthalenes; Niacin; Plasma Exchange; Skin Diseases; Xanthomatosis | 1987 |
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin | 1987 |